The Limited Times

Now you can see non-English news...

Emmanuel Macron announces support measures for laboratories

2020-08-28T19:13:31.408Z


Through these decisions, the president wishes to try to relocate the production of drugs in France.After the declarations of intention to restore the health independence of France undermined during the pandemic, the passage to the act. During a visit on Friday morning to Villeneuve-la-Garenne (Hauts-de-Seine) in the workshops of the Seqens pharmaceutical laboratory, Emmanuel Macron announced two measures to try to relocate the production of drugs in France. Read also: Relocation: paracetamol, ...


After the declarations of intention to restore the health independence of France undermined during the pandemic, the passage to the act. During a visit on Friday morning to Villeneuve-la-Garenne (Hauts-de-Seine) in the workshops of the Seqens pharmaceutical laboratory, Emmanuel Macron announced two measures to try to relocate the production of drugs in France.

Read also: Relocation: paracetamol, the first practical case for labs

First, the drop in the price of drugs, in effect for ten years so as not to dig the hole in Social Security, will be more limited than usual in 2021. There will be a reduction in " the effort that is required. each year to drug companies of 300 million euros for the next financial plan ”, affirmed the President of the Republic. In other words, this contraction in tariffs, which is 900 million this year, will fall to around 600 million next year. " This will help restore the competitiveness of French drug companies, 75% of which have less than fifty employees», Estimates Frédéric Collet, president of Leem (The drug companies) and of the French subsidiary of the laboratory Novartis. Finding a little leeway, laboratories should be less tempted to have their products manufactured abroad.

Speed ​​up the launch

Second decision of the executive, the procedures for marketing drugs will be simplified to accelerate their launch. “The reform of temporary authorizations for use on January 1 is a pillar of this 'France relaunch',” explains Emmanuel Macron. Very appreciated by manufacturers, this formula needed some grooming because, over time, it had become so complex that laboratories gave up using it. " This should strengthen the attractiveness of France to laboratories which, suddenly, will be able to more easily design new drugs and administer them to patients, " says Frédéric Collet. It is urgent: today, only 3% of the molecules developed by biotechs are manufactured in France.

Source: lefigaro

All business articles on 2020-08-28

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.